#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9

• https://x.com/i/web/status/1857779533933396132
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1

EGPA: To RTX or not to RTX? French MAINRITSEG trial underway to determine utility of RTX vs. AZA maintenance therapy Huge anticipation for these results, hopefully next year! #ACR24 @RheumNow https://t.co/POelLpirrI

• https://x.com/Dr_Brian_MD/status/1857484737084047833/photo/1

Hot off the racks: The MITIGATE trial is the 1st RCT for IgG4-RD showing that Inebilizumab significantly reduced flare rates vs PbO by depleting CD19-targeted B cells Game changer? Year in review. @RheumNow #ACR24 @rheumarhyme @marklagacmd @idatan @ljdado https://t.co/CZvdrymIyr

• https://x.com/RHEUMarampa/status/1857776021438595250/photo/1
• https://x.com/RHEUMarampa/status/1857776021438595250/photo/1

Year in review: The MANDARA trial showed benralizumab was non-inferior to mepolizumab for #EGPA @RheumNow #ACR24 @rheumarhyme @doktora_ging https://t.co/k5azGQOECB

• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1
• https://x.com/RHEUMarampa/status/1857773694761762864/photo/1

Looking forward to this Plenary - upadacitinib vs plbo in GCA Similar to GiACTA, 26wk taper w/UPA better than 52wk taper w/PLBO. Too small for safety, but no new rsks Strong argument for DMARDs upfront in GCA... but doesn't help with which 😉 #ACR24 @RheumNow Abstr#0770 https://t.co/MZY4QUazhI

• https://x.com/EBRheum/status/1857773615619453431/photo/1
• https://x.com/EBRheum/status/1857773615619453431/photo/1

MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts completely off GCs Now approved for EGPA Year in Review #ACR24 Pillinger @RheumNow https://t.co/ThLziABvzu

• https://x.com/ericdeinmd/status/1857773289474507223/photo/1

Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7

• https://x.com/Dr_Brian_MD/status/1857502436371607960/photo/1

RA pearls from #ACR24 review course: 1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi. 2. Multimorbidity=Poor outcomes, High risk for mortality. 3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg

• https://x.com/AdelaCastro222/status/1857575812788040158/photo/1
• https://x.com/AdelaCastro222/status/1857575812788040158/photo/1

No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/XY0UVDTAI6 https://t.co/b09FB3niNP

Risk for atypical femoral fracture: 🚨Asian race - 4-6x higher risk Duration of use is greater risk than older age Higher risk when given for osteoporosis than cancer treatment - Compare: osteonecrosis of jaw more common with cancer Rx #ACR24 Review Course @RheumNow https://t.co/V8cD5QWNGp

• https://x.com/ericdeinmd/status/1857473638892441852/photo/1